Pharsight

Anoro Ellipta generic

Anoro Ellipta is an anti-respiratory disease drug owned by Glaxosmithkline. It contains the active ingredients Umeclidinium Bromide and Vilanterol Trifenatate. It was first authorized for market use on 18 December, 2013.

When will Anoro Ellipta generic be available?

The generic version of Anoro Ellipta could be available after 11 April, 2031. This date marks the expiration of the 'US8746242*PED' patent. Note, however, that generic release could be earlier due to a Para IV filing.

Anoro Ellipta uses

Anoro Ellipta is used for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Anoro Ellipta patent expiration

Anoro Ellipta holds a total of 22 drug patents, with the last one - 'US8746242*PED' - expiring on April 11, 2031. This means a generic version of the drug might become available post this date. For more details on the patents, see below:

EPO Oppostions filed on Anoro Ellipta

Anoro Ellipta dosage

Want to ask something?